Genetic diseases are notoriously challenging to treat, especially when each condition requires a tailored approach. With over 10,000 known genetic disorders, developing individual therapies for each ...

In a shock move, the co-founders of German mRNA specialist BioNTech – husband and wife team Uğur Şahin and Özlem Türeci – have said they are leaving to set up a new company. They are due to leave by ...

Siloed data is one of the most significant, yet overlooked, barriers to healthcare growth today; limiting doctors’ capacity to care for patients, diminishing hospital efficiency, and capping the speed ...

The US regulator has not, however, cleared leucovorin for autism spectrum disorder (ASD) itself, stepping back from the furore that broke out last year when President Trump claimed it could be a ...

Steve Sanghera is the CEO and co-founder of Inventus. With over 20 years of experience in technology and telecommunications, his extensive experience has proved crucial to the success of Inventus. The ...

Biologic drugs made up only 5% of prescriptions in the US last year, but accounted for 51% of total drug spending, with many products costing hundreds of thousands of dollars per year. Moreover, only ...

Danish pharmaceutical company Lundbeck has appointed Markus Kede to the role of chief AI officer (CAO), promoting him from the role of head of finance and business planning.

Bristol Myers Squibb has the first positive phase 3 results under its belt for mezigdomide, a second experimental drug in its much-trumpeted celmod development programme for multiple myeloma.

GSK has signed an eleventh-hour agreement to give Alfasigma rights to its primary biliary cholangitis (PBC) therapy linerixibat, which is under regulatory review in most major pharma markets worldwide ...

The pharmaceutical industry is racing to turn its data into scientific intelligence with AI. Now, it’s possible to connect your data and tool ecosystem. There is a gold rush happening in ...

Novartis has started construction of a $1.1 billion biomedical research centre in San Diego, as part of a $23 billion capital investment programme in the US that includes seven new facilities. The 466 ...

The two companies announced today that Hims & Hers will now be able to sell Novo Nordisk's injectable and oral semaglutide products, sold respectively as Ozempic for type 2 diabetes and Wegovy for ...